Abstract
Intraperitoneal treatment with interferon-γ (IFN-γ) has been shown to achieve surgically documented responses in the second-line therapy of ovarian cancer. To assess its efficacy in the first-line therapy, we conducted a randomized controlled trial with 148 patients who had undergone primary surgery for FIGO stage Ic–IIIc ovarian cancer. In the control arm women received 100 mg m–2cisplatin and 600 mg m–2cyclophosphamide, the experimental arm included the above regimen with IFN-γ 0.1 mg subcutaneously on days 1, 3, 5, 15, 17 and 19 of each 28-day cycle. Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82). Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached). Complete clinical responses were observed in 68% with IFN-γ versus 56% in controls (n.s.). Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-γ. Thus, with acceptable toxicity, the inclusion of IFN-γ in the first-line chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C and Mantovani A (1990) Intraperitoneal recombinant γ-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50: 7318–7323
Aulitzky W, Gastl G, Aulitzky WE, Nachbaur K, Lanske B, Kemmler G, Flener R, Frick J and Huber C (1987) Interferon-γ for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. Immunobiology 176: 85–95
Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnem EM, Spiegel RJ and Zighelboim J (1985) Intraperitoneal recombinant α-interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer Res 45: 4447–4453
Billiau A (1996) Interferon-γ: biology and role in pathogenesis. Adv Immunol 62: 61–130
Boehm U, Klamp T, Groot M and Howard JC (1997) Cellular responses to interferon-γ. Annu Rev Immunol 15: 749–795
Colombo N, Peccatori F, Paganin C, Bini S, Brandley M, Mangioni C, Mantovani A and Allavena P (1992) Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 51: 42–46
D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W and Lewis JL (1988) A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 6: 689–695
Dighe AS, Richards E, Old LJ and Schreiber RD (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1: 447–456
Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP and Shawver LK (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diaminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575–4580
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ and Schreiber RD (1998) Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556–7561
Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU and Fidler IJ (1986) Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with recombinant γ-interferon. Cancer Res 46: 5401–5405
Malik STA, Knowles RG, East N, Lando D, Stamp G and Balkwill FR (1991) Antitumor activity of γ-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res 51: 6643–6649
Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K and Steis RG (1988) The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6: 434–445
Mannel DN and Falk W (1983) Interferon-gamma is required in activation of macrophages for tumor cytotoxicity. Cell Immunol 79: 396–402
Marth C, Fuith LC, Böck G, Daxenbichler G and Dapunt O (1989) Modulation of ovarian carcinoma tumor marker CA-125 by γ-interferon. Cancer Res 49: 6538–6542
Marth C, Müller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W, Eibl B, Hynes NE and Daxenbichler G (1990) γ-interferon reduces expression of the protooncogen c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50: 7037–7041
Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Müller-Holzner E, Offner F, Feichtinger H, Zwierzina H and Daxenbichler G (1996) Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67: 826–830
Marth C, Widschwendter M, Kærn J, Jørrgensen N-P, Windbichler G, Zeimet AG, Tropé C and Daxenbichler G (1997) Cisplatin resistance is associated with reduced interferon-γ-sensitivity and increased HER-2 expression in cultured ovarian cancer cells. Br J Cancer 76: 1328–1332
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6
Nehmé A, Julia AM, Jozan S, Chevreau C, Bugat R and Canal P (1994) Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. Eur J Cancer 30A: 550–525
Ozols RF, Rubin SC, Thomas G and Robboy S (1997) Epithelial ovarian cancer. In: Principles and Practice of Gynecologic Oncology, 2nd edn, Hoskins WJ, Perez CA and Young RC (eds), 919–986, Lippincott-Raven: Philadelphia
Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, François E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S and Brandely M (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 14: 343–350
Saito T, Berens ME and Welander CE (1986) Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res 46: 1142–1147
Weisenthal LM, Dill PL and Pearson FC (1991) Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers. J Natl Cancer Inst 83: 37–42
Welander CE, Homesley HD, Reich SD and Levin EA (1988) A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Oncol 11: 465–469
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Windbichler, G., Hausmaninger, H., Stummvoll, W. et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82, 1138–1144 (2000). https://doi.org/10.1054/bjoc.1999.1053
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1053
Keywords
This article is cited by
-
Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer
Journal of Translational Medicine (2024)
-
Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer
Scientific Reports (2023)
-
Radiotherapy enhances CXCR3highCD8+ T cell activation through inducing IFNγ-mediated CXCL10 and ICAM-1 expression in lung cancer cells
Cancer Immunology, Immunotherapy (2023)
-
Th1 cytokines in pediatric acute lymphoblastic leukemia
Cancer Immunology, Immunotherapy (2023)
-
Concurrent application of interferon-gamma and vincristine inhibits tumor growth in an orthotopic neuroblastoma mouse model
Pediatric Surgery International (2023)